204
Participants
Start Date
October 31, 2025
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
LY3537021
Administered SC
Placebo
Administered SC
Standard of Care Antiemetic Therapies
5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally
Background Chemotherapy
Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV
Chang Gung Medical Foundation-Linkou Branch, Taoyuan District
National Cheng Kung University Hospital, Tainan City
Ballarat Health Services, Ballarat Central
Bendigo Health Care Group, Bendigo
Goulburn Valley Health, Shepparton
Latrobe Regional Health, Traralgon
WA Country Health Service Trial Centre, Perth
Laura and Isaac Perlmutter Cancer Center, New York
Taipei Veterans General Hospital, Taipei
Dicle Üniversitesi, Diyarbakır
Trakya University, Edirne
Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi, Gaziantep
FutureMeds - Madrid, Madrid
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Southern Oncology Specialists, Huntersville
Oncology Specialists of Charlotte, Charlotte
Hospital Universitario Virgen de la Victoria, Málaga
Summit Cancer Care, PC, Savannah
Clavis Medical, Miami Lakes
BRCR Global - Tamarac, Tamarac
T.C. Sağlik Bakanliği- Marmara Üniversitesi İstanbul Pendik Eğitim Ve Araştirma Hastanesi, Pendik
Ege Universitesi Hastanesi, Bornova
AULSS8 Berica-Ospedale S.Bortolo, Vicenza
Tennessee Oncology, Nashville
Tennessee Oncology Chattanooga, Chattanooga
North Mississippi Hematology and Oncology Associates, Tupelo
Azienda Ospedaliero Universitaria, Modena
Hospital Universitari Sant Joan de Reus, Reus
Sakarya University School of Medicine, Adapazarı
Azienda Ospedaliera Universitaria Pisana, Pisa
Aou Ospedali Riuniti Umberto I, Ancona
Hope and Healing Cancer Services, Hinsdale
OSF Little Company of Mary Medical Center, Evergreen Park
Centre Leon Berard, Lyon Cedex08
Clinique Victor Hugo Le Mans, Le Mans
Chi Mei Hospital - Liouying Branch, Tainan City
Centre Hospitalier d'Annecy, Epagny Metz-Tessy
John Peter Smith Hospital, Fort Worth
World Research Link, Baytown
UCHealth Harmony, Fort Collins
E-Da Cancer Hospital, Kaohsiung City
Community Cancer Trials of Utah, Ogden
Sainte Catherine Institut du Cancer Avignon Provence, Avignon
Cancer and Blood Specialty Clinic, Los Alamitos
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
BASS Cancer Center, Walnut Creek
Marin Cancer Care, Greenbrae
Asante Rogue Regional Medical Center, Medford
Cancer Care Northwest, Spokane
"Centrul de Oncologie Sfântul Nectarie", Craiova
Zhejiang Provincial People's Hospital, Hangzhou
The First People's Hospital of Changde City, Changde
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang
Zhujiang Hospital, Guangzhou
Ovidius Clinical Hospital OCH, Ovidiu
Jiangmen Center Hospital, Jiangmen
Himeji Medical Center, Himeji
The Cancer Institute Hospital of JFCR, Kōtoku
Kyoto University Hospital, Kyoto
Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun
SC Memorial Healthcare International SRL, Bucharest
Spitalul Clinic Colentina, Bucharest
Spitalul Clinic Colțea, Bucharest
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital de Mataró, Mataró
Adana Medical Park Seyhan Hastanesi, Adana
Ankara Bilkent Şehir Hastanesi, Ankara
Antalya Egitim ve Arastırma Hastanesi, Antalya
Eli Lilly and Company
INDUSTRY